文献速递临床试验与 GCP

经皮冠状动脉介入治疗患者中P2Y12抑制剂单药治疗与双联抗血小板治疗对心血管事件的影响:SMART-CHOICE随机临床试验

Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

SMART-CHOICE试验在韩国33家医院纳入2993例接受药物洗脱支架PCI的患者,随机分为3个月DAPT后P2Y12抑制剂单药组(n=1495)或12个月DAPT组(n=1498)。12个月时主要心脑血管不良事件单药组2.9% vs DAPT组2.5%(差异0.4%,单侧95%CI -∞%至1.3%,非劣效P=0.007),出血单药组显著低于DAPT组(2.0% vs 3.4%;HR 0.58;95%CI 0.36-0.92;P=0.02)。

要点

  • 3个月DAPT后P2Y12抑制剂单药在12个月主要心脑血管不良事件上非劣于12个月DAPT。
  • P2Y12抑制剂单药组出血发生率显著低于DAPT组(2.0% vs 3.4%;HR 0.58;95%CI 0.36-0.92;P=0.02)。
  • 全因死亡、心肌梗死、卒中两组无显著差异。

核心结论

  • 在接受PCI的患者中,与延长DAPT相比,3个月DAPT后P2Y12抑制剂单药治疗的主要心脑血管不良事件发生率非劣效。
  • 由于研究人群和依从性的局限性,需要在其他人群中进一步研究。

研究设计与样本

  • SMART-CHOICE试验为开放标签、非劣效性随机研究,在韩国33家医院开展。
  • 纳入2993例接受药物洗脱支架PCI的患者,入组始于2014年3月18日,随访于2018年7月19日完成。
  • 患者随机接受阿司匹林加P2Y12抑制剂3个月后P2Y12抑制剂单药(n=1495)或DAPT 12个月(n=1498)。
  • 随机化患者平均年龄64岁,女性795例(26.6%),2912例(97.3%)完成试验。

主要发现

  • 12个月时主要心脑血管不良事件(全因死亡、心肌梗死或卒中的复合终点)单药组42例 vs DAPT组36例(2.9% vs 2.5%;差异0.4%;单侧95%CI -∞%至1.3%;非劣效P=0.007)。
  • 全因死亡单药组21例(1.4%)vs DAPT组18例(1.2%)(HR 1.18;95%CI 0.63-2.21;P=0.61)。
  • 心肌梗死单药组11例(0.8%)vs DAPT组17例(1.2%)(HR 0.66;95%CI 0.31-1.40;P=0.28)。
  • 卒中单药组11例(0.8%)vs DAPT组5例(0.3%)(HR 2.23;95%CI 0.78-6.43;P=0.14)。
  • 出血(BARC 2至5型)单药组2.0% vs DAPT组3.4%(HR 0.58;95%CI 0.36-0.92;P=0.02)。

关键数值与推荐

  • 主要终点为术后12个月主要心脑血管不良事件(全因死亡、心肌梗死或卒中的复合终点)。
  • 非劣效界值为1.8%。
  • 次要终点包括主要终点的各组分和BARC 2至5型出血。
  • 方案依从性:P2Y12抑制剂单药组79.3%,DAPT组95.2%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出由于研究人群和依从性的局限性,需要在其他人群中进一步研究。
  • 方案依从性在P2Y12抑制剂单药组为79.3%,在DAPT组为95.2%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Data on P2Y12 inhibitor monotherapy after short-duration dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention are limited. OBJECTIVE: To determine whether P2Y12 inhibitor monotherapy after 3 months of DAPT is noninferior to 12 months of DAPT in patients undergoing PCI. DESIGN, SETTING, AND PARTICIPANTS: The SMART-CHOICE trial was an open-label, noninferiority, randomized study that was conducted in 33 hospitals in Korea and included 2993 patients undergoing PCI with drug-eluting stents. Enrollment began March 18, 2014, and follow-up was completed July 19, 2018. INTERVENTIONS: Patients were randomly assigned to receive aspirin plus a P2Y12 inhibitor for 3 months and thereafter P2Y12 inhibitor alone (n = 1495) or DAPT for 12 months (n = 1498). MAIN OUTCOMES AND MEASURES: The primary end point was major adverse cardiac and cerebrovascular events (a composite of all-cause death, myocardial infarction, or stroke) at 12 months after the index procedure. Secondary end points included the components of the primary end point and bleeding defined as Bleeding Academic Research Consortium type 2 to 5. The noninferiority margin was 1.8%. RESULTS: Among 2993 patients who were randomized (mean age, 64 years; 795 women [26.6%]), 2912 (97.3%) completed the trial. Adherence to the study protocol was 79.3% of the P2Y12 inhibitor monotherapy group and 95.2% of the DAPT group. At 12 months, major adverse cardiac and cerebrovascular events occurred in 42 patients in the P2Y12 inhibitor monotherapy group and in 36 patients in the DAPT group (2.9% vs 2.5%; difference, 0.4% [1-sided 95% CI, -∞% to 1.3%]; P = .007 for noninferiority). There were no significant differences in all-cause death (21 [1.4%] vs 18 [1.2%]; hazard ratio [HR], 1.18; 95% CI, 0.63-2.21; P = .61), myocardial infarction (11 [0.8%] vs 17 [1.2%]; HR, 0.66; 95% CI, 0.31-1.40; P = .28), or stroke (11 [0.8%] vs 5 [0.3%]; HR, 2.23; 95% CI, 0.78-6.43; P = .14) between the 2 groups. The rate of bleeding was significantly lower in the P2Y12 inhibitor monotherapy group than in the DAPT group (2.0% vs 3.4%; HR, 0.58; 95% CI, 0.36-0.92; P = .02). CONCLUSIONS AND RELEVANCE: Among patients undergoing percutaneous coronary intervention, P2Y12 inhibitor monotherapy after 3 months of DAPT compared with prolonged DAPT resulted in noninferior rates of major adverse cardiac and cerebrovascular events. Because of limitations in the study population and adherence, further research is needed in other populations. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02079194.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Hahn JY, Song YB, Oh JH, et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA. 2019. PMID: 31237645. doi:10.1001/jama.2019.8146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。